Table 1 Patients’ characteristics and outcomes according to planned ICU admission or not.

From: Prognostic and risk factor analysis of cancer patients after unplanned ICU admission: a real-world multicenter study

Variables

Total (n = 1488)

Planned ICU admission (n = 566)

Unplanned ICU admission (n = 922)

p

Type of cancer, n (%)

 < 0.001

 Esophageal cancer

607 (40.8)

272 (48.1)

335 (36.3)

 

 Lung cancer

285 (19.2)

79 (14)

206 (22.3)

 

 Abdominal cavity tumor

211 (14.2)

82 (14.5)

129 (14)

 

 Gynecological tumor

121 ( 8.1)

35 (6.2)

86 (9.3)

 

Age, mean ± SD

63.2 ± 12.4

64.9 ± 12.6

62.2 ± 12.2

 < 0.001

Sex, n (%)

   

0.364

 Male

575 (38.6)

227 (40.1)

348 (37.7)

 

 Female

913 (61.4)

339 (59.9)

574 (62.3)

 

BMI, mean ± SD

22.6 ± 3.7

23.3 ± 3.8

22.1 ± 3.7

 < 0.001

Basic diseases

 Hypertension, n (%)

 < 0.001

  No

1015 (68.2)

357 (63.1)

658 (71.4)

 

  Yes

473 (31.8)

209 (36.9)

264 (28.6)

 

 Chronic respiratory insufficiency, n (%)

0.061

  No

1463 (98.3)

561 (99.1)

902 (97.8)

 

  Yes

25 ( 1.7)

5 (0.9)

20 (2.2)

 

 Chronic hepatic insufficiency, n (%)

0.071

  No

1467 (98.6)

562 (99.3)

905 (98.2)

 

  Yes

21 ( 1.4)

4 (0.7)

17 (1.8)

 

 Chemotherapy, n (%)

 < 0.001

  No

1108 (74.5)

491 (86.7)

617 (66.9)

 

  Yes

380 (25.5)

75 (13.3)

305 (33.1)

 

 Radiotherapy, n (%)

   

 < 0.001

  No

1401 (94.2)

557 (98.4)

844 (91.5)

 

  Yes

87 (5.8)

9 (1.6)

78 (8.5)

 

Source of transfer, n (%)

 < 0.001

 Operating room

601 (40.4)

490 (86.6)

111 (12)

 

 Emergency room

65 (4.4)

1 (0.2)

64 (6.9)

 

 General ward

805 (54.1)

69 (12.2)

736 (79.8)

 

 Other hospital

17 (1.1)

6 (1.1)

11 (1.2)

 

 Surger or not

   

 < 0.001

  No

549 (36.9)

14 (2.5)

535 (58)

 

  Yes

939 (63.1)

552 (97.5)

387 (42)

 

Organ function and support, n (%)

 APACHE II, Median (IQR)

12.0 (8.0, 17.0)

9.0 (6.0, 11.8)

15.0 (11.0, 20.0)

 < 0.001

 SOFA, median (IQR)

3.0 (2.0, 6.0)

2.0 (1.0, 3.0)

4.0 (3.0, 7.0)

 < 0.001

 Leukocyte grading

 < 0.001

  3.0-normal

1387 (93.2)

558 (98.6)

829 (89.9)

 

  2.0–3.0

26 (1.7)

3 (0.5)

23 (2.5)

 

  1.0–2.0

25 (1.7)

2 (0.4)

23 (2.5)

 

  < 1.0

49 (3.3)

2 (0.4)

47 (5.1)

 

 Granulocyte grading

 < 0.001

  1.5-normal

1394 (93.7)

558 (98.6)

836 (90.7)

 

  1.0–1.5

18 (1.2)

3 (0.5)

15 (1.6)

 

  0.5–1.0

15 (1.0)

0 (0)

15 (1.6)

 

  < 0.5

60 (4.0)

4 (0.7)

56 (6.1)

 

 Grade four myelosuppression

 < 0.001

  No

1297 (87.2)

541 (95.6)

756 (82)

 

  Yes

191 (12.8)

25 (4.4)

166 (18)

 

 Sepsis

   

 < 0.001

  No

548 (36.8)

373 (65.9)

175 (19)

 

  Yes

940 (63.2)

193 (34.1)

747 (81)

 

 Respiratory failure

 < 0.001

  No

922 (62.0)

468 (82.7)

454 (49.2)

 

  Yes

566 (38.0)

98 (17.3)

468 (50.8)

 

 Conventional oxygen therapy

 < 0.001

  No

234 (15.7)

32 (5.7)

202 (21.9)

 

  Yes

1254 (84.3)

534 (94.3)

720 (78.1)

 

 High flow oxygen therapy

 < 0.001

  No

1131 (76.0)

487 (86)

644 (69.8)

 

  Yes

357 (24.0)

79 (14)

278 (30.2)

 

 Noninvasive ventilation

0.004

  No

1429 (96.0)

554 (97.9)

875 (94.9)

 

  Yes

59 ( 4.0)

12 (2.1)

47 (5.1)

 

 Invasive ventilation

0.002

  No

896 (60.2)

369 (65.2)

527 (57.2)

 

  Yes

592 (39.8)

197 (34.8)

395 (42.8)

 

 Shock

   

 < 0.001

  No

1076 (72.3)

490 (86.6)

586 (63.6)

 

  Yes

412 (27.7)

76 (13.4)

336 (36.4)

 

 Use of vasoactive drugs

 < 0.001

  No

1046 (70.3)

474 (83.7)

572 (62)

 

  Yes

442 (29.7)

92 (16.3)

350 (38)

 

 AKI

   

 < 0.001

  No

1313 (88.2)

549 (97)

764 (82.9)

 

  Yes

175 (11.8)

17 (3)

158 (17.1)

 

 CRRT

   

 < 0.001

  No

1406 (94.5)

561 (99.1)

845 (91.6)

 

  Yes

82 ( 5.5)

5 (0.9)

77 (8.4)

 

Clinical outcome

 ICU stay, median (IQR)

4.0 (2.0, 7.0)

3.0 (2.0, 6.0)

5.0 (3.0, 8.0)

 < 0.001

 Hospital stay, median (IQR)

18.0 (12.0, 28.0)

18.0 (12.0, 26.0)

19.0 (12.0, 28.0)

0.057

 ICU motality, n (%)

   

 < 0.001

  No

1400 (94.1)

562 (99.3)

838 (90.9)

 

  Yes

88 ( 5.9)

4 (0.7)

84 (9.1)

 

 Hospital motality, n (%)

   

 < 0.001

  No

1380 (92.7)

560 (98.9)

820 (88.9)

 

  Yes

108 ( 7.3)

6 (1.1)

102 (11.1)

 

 Anti-tumor therapy after transfer out, n (%)

   

 < 0.001

  No

1000 (67.2)

327 (57.8)

673 (73)

 

  Yes

488 (32.8)

239 (42.2)

249 (27)

 

Tumor progression-related death,n(%)

   

 < 0.001

NO

1252 (84.1)

549 (97)

703 (76.2)

 

YES

236 (15.9)

17 (3)

219 (23.8)

 

 Non-tumor progression-related death, n (%)

   

 < 0.001

  No

1309 (88.0)

544 (96.1)

765 (83)

 

  Yes

179 (12.0)

22 (3.9)

157 (17)

 

 Survival 90 days, n (%)

   

 < 0.001

  Yes

1073 (72.1)

527 (93.1)

546 (59.2)

 

  No

415 (27.9)

39 (6.9)

376 (40.8)

 
Back to article page